Summary
84 / 100 · Bulios Score
What speaks for it
- Out of every 100 HUF of revenue, 25 HUF is left as net profit.
- It holds more cash than debt: 269.1B Ft against 19.2B Ft.
- The share price is below the Bulios Fair Price.
- It earns 17 HUF a year on every 100 HUF of invested capital.
What to watch
- Revenue grew by only 2.4% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 6.4 HUF for 1 HUF of yearly profit. Over the last five years it was 9.0 HUF on average.
Valuation in detailIs it growing?
SlowlyRevenue (HUF)
Diluted EPS (HUF)
- Analyst estimate
Revenue grew by 8.8% a year over 5 years. Over the last 3 years it grew by 2.4% a year. Earnings per share grew by 9.1% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 HUF of revenue goes
- Cost of sales 32 HUF
- Research and development 9.8 HUF
- Sales and administration 25 HUF
- Taxes and other 8.8 HUF
- Net profit 25 HUF
Net profit, industry median (Medical - Pharmaceuticals) 4.8 HUF
Out of every 100 HUF of revenue, 25 HUF is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
High, stretched- Yield
- 8.62%
- Paid out of profit
- 55%
- Raised in a row
- 3 years
You receive $2.14 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.